At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are comparing two new combination drug treatments with the standard therapy for multiple myeloma. The people in this study have multiple myeloma that is newly diagnosed. In addition, they cannot have an autologous stem cell transplant with high-dose chemotherapy.
-
The purpose of this study is to find the highest dose of the investigational drug codrituzumab that can be given safely in children and young adults with solid tumors that came back or continued to grow despite treatment. Codrituzumab works by targeting a protein called GPC3, which can drive the growth of some forms of cancer that affect children and young adults. It is given intravenously (by vein).
- A Phase 3 Study Assessing Dara-VCD Chemotherapy Alone or With a Stem Cell Transplant for People With Newly Diagnosed AL Amyloidosis
Full Title A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis (S2213) (CIRB)
Purpose
Researchers are comparing combination chemotherapy alone or with a stem cell transplant for people with amyloid light chain (AL) amyloidosis. The people in this study have newly diagnosed AL amyloidosis. The chemotherapy includes daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD).
If you join this study, you will be randomly assigned to get one of these treatments:
- Dara-VCD alone.
- Dara-VCD followed by a stem cell transplant with melphalan. Giving melphalan before a stem cell transplant helps kill cancer cells and makes room for new blood-forming cells to grow.
A stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in people with newly diagnosed AL amyloidosis.
Who Can Join
To join this study, there are a few conditions. You must:
- Have newly diagnosed AL amyloidosis.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Heather Landau’s office at 646-608-3740.
Protocol
25-107Phase
Phase III (phase 3)Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT06022939ClinicalTrials.gov
-
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.
-
Researchers want to find the best schedule for giving a new vaccine to people with neuroblastoma. The people in this study have neuroblastoma that is in remission (no signs of cancer). In addition, their cancers have a strong chance of coming back (high risk). The vaccine is given with a naturally occurring substance called beta-glucan.
-
Researchers are assessing the iberdomide with belantamab mafodotin and dexamethasone in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even with treatment.
-
Researchers are comparing treatment with doxorubicin chemotherapy and pembrolizumab immunotherapy to doxorubicin alone for advanced sarcoma. The people in this study have undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery).
- A Phase 2 Study of Venetoclax and Revumenib in People With Acute Myeloid Leukemia
Full Title A Multi-site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Purpose
Researchers want to find the best dose of revumenib to give with venetoclax in people with acute myeloid leukemia (AML). The people in this study have AML with minimal residual disease. This means they have a small number of cancer cells remaining in their bodies after treatment. In addition, their cancers have a mutation (change) in the NPM1, KMT2A, or NUP98 genes.
Venetoclax blocks Bcl-2, a protein that helps cancer cells survive and resist the effects of anti-cancer treatments. By blocking Bcl-2, venetoclax may cause the death of cancer cells or make them more sensitive to other treatments. It is taken orally (by mouth).
Revumenib is designed to block a protein called menin, which leukemia cells need to divide. By blocking menin, revumenib may prevent cancer cells from growing, stop them from spreading, or make them shrink. It is also taken orally.
Giving venetoclax and revumenib in combination may work better against AML than using either drug alone.
Who Can Join
To join this study, there are a few conditions. You must:
- Have AML with minimal residual disease and a mutation in the NPM1, KMT2A, or NUP98 genes.
- Not be planning to have a stem cell transplant in the next 30 days.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 12 or older.
Contact
For more information or to see if you can join this study, please call Dr. Aaron Goldberg’s office at 646-608-3752.
Protocol
25-179Phase
Phase I/II (phases 1 and 2 combined)Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT06284486ClinicalTrials.gov
- A Study of Cord Blood Transplantation in Children and Young Adults with Blood Cancers and Non-Cancerous Blood Disorders
Full Title Cord Blood Transplantation in Children and Young Adults with Hematologic Malignancies and Non-Malignant Disorders
Purpose
The transplantation of stem cells from umbilical cord blood is a treatment for some blood cancers and non-cancerous blood or metabolic disorders. Patients routinely receive high doses of chemotherapy and sometimes radiation before receiving the stem cells to help make room in the bone marrow for new blood stem cells to grow, prevent the body from rejecting the transplanted cells, and help kill any abnormal blood cells in the body. However, the combination of these treatments can have serious side effects.
Researchers are doing this study to find out whether a combination of the chemotherapy drugs clofarabine, fludarabine, and busulfan (without radiation) is a safe and effective treatment for children and young adults receiving cord blood transplants for blood cancers or non-cancerous blood or metabolic disorders. These three drugs are given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a blood cancer or non-cancerous blood disorder and be candidates for umbilical cord transplantation. Examples of blood cancers include acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), advanced myelodysplasia (MDS), chronic myelogenous leukemia (CML), myeloproliferative disorders, and non-Hodgkin and Hodgkin lymphoma. Examples of non-cancerous disorders include inherited metabolic diseases, Hurler syndrome, Hunter disease, Sly syndrome, alpha-mannosidosis, X-ALD (X-linked adrenoleukodystrophy), osteopetrosis, metachromatic leukodystrophy, globoid cell leukodystrophy, bone marrow failure syndromes, and diseases like HLH (hemophagocytic lymphohistiocytosis) caused by a compromised immune system.
- This study is for patients age 21 and younger.
For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.
Protocol
20-480Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04644016ClinicalTrials.gov
-
Researchers want to see how well ivonescimab works as a treatment for endometrial and cervical cancers. The people in this study have endometrial or cervical cancer that keeps growing after treatment.